Skip to main content

Atrial Fibrillation clinical trials at UCSD

4 in progress, 2 open to eligible people

Showing trials for
  • Amplatzer Amulet LAAO vs. NOAC

    open to eligible people ages 18 years and up

    The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.

    San Diego, California and other locations

  • iCLAS™ for Persistent Atrial Fibrillation

    open to eligible people ages 18-80

    Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF). Data will be used to support a pre-market application (PMA)

    San Diego, California and other locations

  • Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF

    Sorry, not currently recruiting here

    This prospective randomized study will assess the safety and efficacy of FIRM-guided ablation (FIRM+PVI) compared to pulmonary vein isolation (PVI) without FIRM, for the treatment of symptomatic atrial fibrillation.

    San Diego, California and other locations

  • TactiFlex AF IDE Trial

    Sorry, in progress, not accepting new patients

    Prospective non-randomized parallel-assignment multi-center clinical investigation. The study design includes two subject cohorts: 1) PAF Main Study, and 2) PAF High Standard Power (HSP) Substudy. Subjects in the main study cohorts are to be treated using the full range of ablation power settings in the IFU. Subjects in the HSP Substudy are to be treated in the upper end of the recommended ablation power settings (40-50 Watts).

    San Diego, California and other locations

Our lead scientists for Atrial Fibrillation research studies include .

Last updated: